Immunotherapy: function of checkpoint inhibitor and current problem

Ketong Lin

doi:10.1117/12.2692043

7 September 2023 Immunotherapy: function of checkpoint inhibitor and current problem

Ketong Lin

Proceedings Volume 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023); 127890C (2023) https://doi.org/10.1117/12.2692043
Event: International Conference on Modern Medicine and Global Health (ICMMGH 2023), 2023, Oxford, United Kingdom

Abstract

Cancer continues to be a very challenging disease to treat at this time. In recent years, research has demonstrated that checkpoint inhibitors are a treatment for cancer as well as one of the immunotherapies. Moreover, these inhibitors are classified as immunotherapies. Checkpoint inhibitor medications include nivolumab and ipilimumab, among others. The checkpoint proteins PD-1 and CTLA-2 are often prevented from functioning properly by these medications. This medication will also be effective at inhibiting the activity of another type of checkpoint protein known as PD-L1. The effectiveness of checkpoint blockade in the fight against cancer has been shown in several trials. Despite this, there are still some concerns that have been raised about the situation. Toxicity of immune checkpoint inhibitor still remain a problem need to improve. The fact that cTLA-2 has no impact on immunotherapy is one of the problems that will require further investigation in the near and distant futures.

Citation Download Citation

Ketong Lin "Immunotherapy: function of checkpoint inhibitor and current problem", Proc. SPIE 12789, International Conference on Modern Medicine and Global Health (ICMMGH 2023), 127890C (7 September 2023); https://doi.org/10.1117/12.2692043

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available